Collaboration between the pharmaceutical industry and Healthcare Professionals (HCPs) or Healthcare Organizations (HCOs) benefits patients. It is a relationship that has delivered numerous break-through medicines and changed the way many diseases impact patients’ lives. Our work together includes a range of activities from clinical research to sharing best clinical practice. As an industry we make payments or ‘transfers of value’ to Healthcare Professionals and Organizations to compensate them for the time spent working with us.
Bringing greater transparency to this already well-regulated relationship builds understanding of this collaboration and addresses public concerns about interactions between the medical community and the pharmaceutical industry. We believe that openly communicating payments helps foster trust with patients, Healthcare Professionals, government officials and the public, and supports our overall commitment to data transparency and high ethical business standards. Novartis has long been dedicated to improving clinical trial data transparency and discloses relationships with patient organizations.
In several countries, we publish payments to Healthcare Professionals and Organizations in line with local laws or regulations.
About our Reporting Practices
Europe
Across Europe, Novartis discloses annually payments and other transfers of value in line with the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure Code and its local transpositions. The EFPIA Disclosure Code 2024 Self-Certification Letter (PDF 0.4 MB) signed by Patrick Horber, Novartis President, International, confirms the application of the principles of the EFPIA Disclosure Code. The letter from previous year is available here (PDF 0.1 MB).
Novartis also complies with the Medicines for Europe (European Generic and Biosimilar Medicines Association) Transparency Rules and Requirements, which defines disclosure rules for the generic, biosimilar and value added medicines industry.
Following the spin-off of Sandoz from Novartis in November 2023, Novartis will still be responsible for publishing the 2023 Transparency of Value (ToV) for Sandoz, covering 2023 ToV reporting. However, from 2025 onwards, only Novartis's ToV will be published. This means that any transparency and disclosure related to Sandoz for 2024 will not be included in Novartis's publications and starting from 2025, Sandoz will handle its own reporting separately.
United States
Novartis Pharmaceuticals Corporation (NPC) is required each year to submit data to the Centers for Medicare and Medicaid Services (CMS) Open Payments program (commonly known as the Sunshine Act) as an applicable manufacturer. CMS collects information about certain payments and other transfers of value from applicable manufacturers and group purchasing organizations (GPOs) to physicians and teaching hospitals. Open Payments is the federally run transparency program that collects information about these financial relationships and makes it available to the public annually through the CMS Open Payments website.
Read more about our Payments to Healthcare Professionals in the United States.
Rest of the world
In addition to the EFPIA countries and the United States, we publicly disclose payments and transfers of value in Australia, Brazil, Colombia, Canada, Israel, Japan and New Zealand. In Chile, Indonesia, Pakistan, Philippines and Saudi Arabia, transfers of value are reported to the government. In South Korea, transfers of value are gathered and shared with the Ministry of Health upon request.